Custom Armed Viral Vectors

Genelux Corporation is singular in its abilities to efficiently design custom viral vectors a capability which is the basis of the Company’s deep pipeline for future drug candidates. Leveraging the unique mechanisms by which its proprietary vaccinia platform preferentially targets and kills tumor cells, the company has already designed over 300 viral constructs with more than 60 unique transgenes or proteins, and the possibilities for constructing custom targeted vectors are virtually limitless. These attenuated, replication competent proprietary Genelux vectors will allow the insertion of Your Favorite Gene(s) at any of three loci for delivery amplification and protein production directly within tumor cells.

“Customized” Anti-tumor Vectors: Therapeutic Antibody Gene Enhances the Anti-Tumor Effect of Vaccinia Oncolytic Virotherapy

Bevacizumab, Genetech’s anti-angiogeneis drug Avastin® , seeks to inhibit the formation of blood vessels in the tumor, effectively “starving” the tumor and stunting its growth. However, many such antibodies cannot efficiently penetrate tumors, ultimately limiting their effectiveness even when patients are given extremely costly high doses. To overcome these limitations, Genelux scientists successfully designed vaccinia vectors to carry and over-express an engineered single-chain Avastin-like antibody (GLAF-1) directly to tumors, while simultaneously retaining its oncolytic potency (replication and tumor cell lysis.)

The graph below shows the results of virotherapy with the two vectors (GLV-108 and GLV-109) as compared with the Genelux parent oncolytic virus GL-ONC1 not encoding GLAF-1, and control mice (no treatment) in pancreatic cancer xenografts. The vectors engineered to over-express GLAF-1 significantly enhanced therapeutic effects compared to the control mice, over Avastin therapy alone, and even resulted in enhanced therapeutic benefit over GL-ONC1 alone. This approach points to an exciting new therapeutic concept: tumor-specific, locally “manufactured” anti-cancer therapy in humans.